Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPIVACAINE HYDROCHLORIDE vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (epidural),Postoperative pain management,Off-label: peripheral nerve blocks, sympathetic nerve blocks
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Primarily hepatic via conjugation with glucuronic acid; CYP3A4 and CYP1A2 involved in metabolism to pipecoloxylidine and desbutylbupivacaine.
Hydrolyzed by plasma esterases.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Renal excretion of parent drug and metabolites: <5% unchanged.
Approximately 95% bound to alpha-1-acid glycoprotein (AAG) and albumin; binding is concentration-dependent and decreases in acidosis.
Minimal; <5% bound to plasma proteins.
Vd: 0.73 L/kg (range 0.5-1.0 L/kg) in adults; reflects extensive tissue binding; lower in neonates (0.3-0.6 L/kg) due to reduced adipose tissue.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Not applicable for intravenous use; epidural: ~100% (systemic absorption from epidural space); peripheral nerve block: variable (systemic absorption depends on site and dose); oral: negligible (<5%) due to extensive first-pass metabolism.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: use with caution, reduce dose by 25% and monitor for toxicity. For GFR <10 m L/min: avoid or reduce dose by 50% with close monitoring.
No dose adjustment required; negligible systemic absorption.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: contraindicated or use minimal effective dose with extreme caution.
No dose adjustment required; negligible systemic absorption.
Infants and children: 0.25-0.5% solution, maximum 2 mg/kg (without epinephrine) or 3 mg/kg (with epinephrine), not to exceed 175 mg total.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Elderly patients: reduce dose by 25-50% due to decreased clearance and increased sensitivity; consider lower concentrations and volumes; avoid rapid infusion.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Risk of cardiac arrest and death following unintended intravenous injection or administration of high doses; resuscitation may be difficult and prolonged.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Avoid for spinal anesthesia when high doses are needed due to neurotoxicity risk,Monitor for signs of CNS and cardiovascular toxicity,Use in pregnant women only if clearly needed (Category C)
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Hypersensitivity to bupivacaine or other amide anesthetics,Severe hypotension (e.g., hypovolemic shock),Inflammation or sepsis at injection site,Paracervical block in obstetrics (associated with fetal bradycardia),Use for intravenous regional anesthesia (Bier block)
Hypersensitivity to any component of the formulation.
No known food interactions. Grapefruit juice may affect hepatic metabolism via CYP3A4 inhibition, but clinical significance is minimal. Maintain normal diet.
None known.
Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second and third trimesters: risk of fetal bradycardia and acidosis due to placental transfer. Epidural use may cause maternal hypotension reducing uteroplacental perfusion. Avoid paracervical block in pregnancy due to risk of fetal bradycardia.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.30. It is considered compatible with breastfeeding; however, monitor infant for signs of local anesthetic toxicity such as drowsiness or irritability.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Increased plasma volume and decreased plasma protein binding in pregnancy may require reduced doses to avoid toxicity. However, standard epidural doses often remain similar; dose adjustment should be based on clinical response and weight. Use lower doses for combined spinal-epidural. Maximum single epidural dose: 2.5 mg/kg (non-pregnant), but in pregnancy consider 2.0 mg/kg due to increased sensitivity.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
Bupivacaine is a long-acting amide local anesthetic. Maximum single dose is 2.5 mg/kg (with epinephrine 3 mg/kg). Cardiotoxicity is greater than lidocaine; avoid intravascular injection. Use with caution in hepatic impairment. For labor analgesia, 0.0625-0.125% with fentanyl is common. Adding epinephrine prolongs duration and reduces peak plasma concentration.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Report any numbness or tingling beyond expected area of anesthesia.,Seek immediate medical attention if you experience ringing in ears, metallic taste, dizziness, or seizures.,Inform your healthcare provider if you have liver disease or are taking antiarrhythmics.,Avoid driving or operating machinery until full sensation returns.,Do not apply heat or cold to the numb area to prevent burns or frostbite.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPIVACAINE HYDROCHLORIDE vs ALCAINE, answered by our medical review team.
BUPIVACAINE HYDROCHLORIDE is a Local Anesthetic that works by Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPIVACAINE HYDROCHLORIDE and ALCAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPIVACAINE HYDROCHLORIDE is: 0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPIVACAINE HYDROCHLORIDE and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPIVACAINE HYDROCHLORIDE is classified as Category C. Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second . ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.